AR091075A1 - Proceso para preparar derivados monociclicos de heteroaril-cicloalquil-diamina - Google Patents
Proceso para preparar derivados monociclicos de heteroaril-cicloalquil-diaminaInfo
- Publication number
- AR091075A1 AR091075A1 ARP130101712A ARP130101712A AR091075A1 AR 091075 A1 AR091075 A1 AR 091075A1 AR P130101712 A ARP130101712 A AR P130101712A AR P130101712 A ARP130101712 A AR P130101712A AR 091075 A1 AR091075 A1 AR 091075A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- solvent
- derivative
- typically
- reacted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
Abstract
Reivindicación 1: Un proceso para la fabricación de un compuesto de la fórmula (8), o una sal farmacéuticamente aceptable del mismo, en donde X¹ es CH o N; Y¹, Y² e Y³ dependen de la posición del enlace doble CH, NH o N; R¹ es H, alquilo, CN, o Hal; y R² es H, alquilo, o Hal; en donde se presenta en conformidad con el esquema mostrado más adelante, un derivado de ácido carboxílico de fórmula (1), en donde Alk es alquilo y típicamente es etilo, se hace reaccionar con un derivado de amino-indol o amino-indazol de fórmula (2) en presencia o ausencia de un solvente, ej., en presencia de un solvente aprótico tal como NMP, para proporcionar el intermedio de indol o indazol de fórmula (3), en donde si un grupo amino libre está presente dicho grupo amino es luego protegido en un paso de protección opcional, ej., al reaccionar el derivado de indol o derivado de indazol de fórmula (3) ej., con un agente de esterificación tal como BOC₂O típicamente en presencia de una base tal como DMPA y un solvente tal como THF para proporcionar el indol protegido de fórmula (4), el cual se hace reaccionar con amoniaco típicamente en presencia de un solvente tal como metanol, o etanol o una mezcla de los mismos para proporcionar la amida del ácido carboxílico de fórmula (5), tal amida de fórmula (5) se activa primero, ej., al reaccionar con un peroxiácido orgánico tal como ácido perbenzóico o MCPBA y luego se hace reaccionar con derivado de ciclohexanediamina de fórmula (6) típicamente en presencia de una base tal como trietilamina y un solvente tal como DMF para proporcionar el derivado protegido de fórmula (7), que se hace reaccionar con un ácido para retirar los grupos protectores, tal como TFA o HCl típicamente en presencia de un solvente tal como diclorometano o metanol para proporcionar un compuesto de la fórmula (8), el cual puede opcionalmente hacerse reaccionar con un ácido apropiado para proporcionar una sal, ej., una sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647675P | 2012-05-16 | 2012-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091075A1 true AR091075A1 (es) | 2014-12-30 |
Family
ID=48699891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101712A AR091075A1 (es) | 2012-05-16 | 2013-05-17 | Proceso para preparar derivados monociclicos de heteroaril-cicloalquil-diamina |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20130310387A1 (es) |
| EP (1) | EP2850076A1 (es) |
| JP (1) | JP2015516462A (es) |
| CN (1) | CN104302641A (es) |
| AR (1) | AR091075A1 (es) |
| TW (1) | TW201400477A (es) |
| UY (1) | UY34807A (es) |
| WO (1) | WO2013171690A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9040530B2 (en) | 2012-06-22 | 2015-05-26 | Portola Pharmaceuticals, Inc. | 1,2,4-triazine-6-carboxamide kinase inhibitors |
| MA38072A1 (fr) | 2012-11-08 | 2016-07-29 | Bristol Myers Squibb Co | Composés hétérocycliques substitués par amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn? |
| WO2014111031A1 (zh) * | 2013-01-17 | 2014-07-24 | 四川恒康发展有限责任公司 | 三嗪化合物、其药用盐、异构体或水合物及其药物组合物 |
| CN106083821B (zh) * | 2016-06-22 | 2019-01-11 | 上海皓元生物医药科技有限公司 | 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法 |
| WO2021170046A1 (en) * | 2020-02-26 | 2021-09-02 | Beigene, Ltd. | Tyk-2 inhibitor |
| WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| US5981262A (en) | 1993-04-23 | 1999-11-09 | Ariad Pharmaceuticals, Inc. | Human syk |
| ATE236973T1 (de) | 1993-07-16 | 2003-04-15 | Gen Hospital Corp | Änderung der zellulären immunität durch rezeptorchimäre |
| JPH08242859A (ja) | 1993-09-30 | 1996-09-24 | Tonen Corp | ヒトマスト細胞由来蛋白質燐酸化酵素遺伝子 |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| AU5107900A (en) | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| WO2001040800A2 (en) | 1999-11-30 | 2001-06-07 | Parker Hughes Institute | Syk localized at centrosome |
| JP2004203748A (ja) | 2002-12-24 | 2004-07-22 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，２−ｃ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
| AU2004293035A1 (en) | 2003-11-19 | 2005-06-09 | Signal Pharmaceuticals, Llc | Methods of treating diseases and disorders by targeting multiple kinases |
| US8057815B2 (en) | 2004-04-19 | 2011-11-15 | Portola Pharmaceuticals, Inc. | Methods of treatment with Syk inhibitors |
| US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| US20080070256A1 (en) | 2006-07-26 | 2008-03-20 | National Jewish Medical And Research Center | Non-Human Animal Models for B-cell Non-Hodgkin's Lymphoma and Uses Thereof |
| BRPI0814777A2 (pt) | 2007-08-08 | 2015-03-03 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. |
| RU2493152C2 (ru) * | 2008-02-01 | 2013-09-20 | Акинион Фармасьютикалз Аб | Новые соединения, применение и получение их |
| KR101773313B1 (ko) | 2008-04-16 | 2017-08-31 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
| US9551710B2 (en) | 2010-02-09 | 2017-01-24 | Drexel University | Signaling molecule involved in ultraviolet damage to skin |
| PL2589592T3 (pl) | 2010-06-30 | 2019-03-29 | Fujifilm Corporation | Nowe pochodne nikotynamidu lub ich sole |
| CA2808165A1 (en) | 2010-08-18 | 2012-02-23 | Universite Laval | Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (dcir) activity and signaling events |
| WO2012044936A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
| US20130252917A1 (en) | 2010-09-30 | 2013-09-26 | Portola Pharmaceuticals, Inc. | Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine |
| CN103282352B (zh) | 2010-11-01 | 2016-08-10 | 波托拉医药品公司 | 作为syk调节剂的苯甲酰胺类和烟酰胺类 |
| WO2012071042A1 (en) | 2010-11-24 | 2012-05-31 | Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services | Compositions and methods for treating or preventing lupus |
| WO2013047813A1 (ja) * | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
-
2013
- 2013-05-13 US US13/892,359 patent/US20130310387A1/en not_active Abandoned
- 2013-05-13 UY UY0001034807A patent/UY34807A/es not_active Application Discontinuation
- 2013-05-15 JP JP2015512183A patent/JP2015516462A/ja active Pending
- 2013-05-15 EP EP13731933.1A patent/EP2850076A1/en not_active Withdrawn
- 2013-05-15 US US14/400,545 patent/US9290481B2/en not_active Expired - Fee Related
- 2013-05-15 CN CN201380025279.2A patent/CN104302641A/zh active Pending
- 2013-05-15 WO PCT/IB2013/053970 patent/WO2013171690A1/en active Application Filing
- 2013-05-16 TW TW102117444A patent/TW201400477A/zh unknown
- 2013-05-17 AR ARP130101712A patent/AR091075A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150152087A1 (en) | 2015-06-04 |
| CN104302641A (zh) | 2015-01-21 |
| UY34807A (es) | 2013-12-31 |
| TW201400477A (zh) | 2014-01-01 |
| WO2013171690A1 (en) | 2013-11-21 |
| JP2015516462A (ja) | 2015-06-11 |
| EP2850076A1 (en) | 2015-03-25 |
| US9290481B2 (en) | 2016-03-22 |
| US20130310387A1 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091075A1 (es) | Proceso para preparar derivados monociclicos de heteroaril-cicloalquil-diamina | |
| ES2924193T3 (es) | Procesos e intermedios para preparar un medicamento | |
| ES2585330T3 (es) | Compuesto heterocíclico que contiene nitrógeno que tiene un efecto inhibitorio en la producción de quinurenina | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| AR095217A1 (es) | Métodos para síntesis estereoselectiva de análogos de nucleósidos sustituidos | |
| CO6220963A2 (es) | Cocristales y composiciones farmaceuticas que los comprenden | |
| ES2764223T3 (es) | Procedimiento de producción de un derivado de espirooxindol | |
| ES2582471T3 (es) | Inhibidores polibásicos de la bomba de flujo de salida bacteriana que contienen boro y usos terapéuticos de los mismos | |
| PE20150041A1 (es) | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco | |
| AR085806A1 (es) | Inhibidores triciclicos de girasa | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| PE20110417A1 (es) | Proceso para la preparacion de derivados de l-alanina protegidos | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| MX2015007193A (es) | Ligando de receptor de neurotensina. | |
| ES2570628T3 (es) | Nuevas arilamidas con sustitución imidazol | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| AR105091A1 (es) | Procedimiento para la síntesis de derivados de rapamicina | |
| AR049668A1 (es) | Proceso quimico para preparar esteres de 4,4 - difluorometil - 3 - oxo - butanoico por reaccion entre una amida y un ester. | |
| AR072396A1 (es) | Proceso para preparar derivados de pirimidina sustituidos | |
| ES2688812T3 (es) | Conjugados de LLP2A-bisfosfonato para el tratamiento de la osteoporosis | |
| AR071005A1 (es) | Preparacion selectiva de pirimidinas sustituidas | |
| ES2657972T3 (es) | Derivado de tirosina y método de fabricación de un derivado de tirosina | |
| ATE486886T1 (de) | Neue betulinsäurederivate kondensiert im a-ring mit einer heterozyklischen gruppe | |
| ES2716750T3 (es) | Procedimiento de producción de un derivado del ácido valérico ópticamente activo | |
| KR20130090360A (ko) | 물 또는 다양한 산을 첨가제로 이용한 새로운 마이클-첨가 반응을 통하여 화합물을 제조하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |